Synotrac

Total joint arthroplasty (TJA) is the replacement of damaged tissue and bone with a biocompatible prosthesis. Over 1.3 million TJAs are performed annually in the US, and over 40,000 revision surgeries are required because of periprosthetic joint infection (PJI), a bacterial infection at the site of the implant. Doctors currently wait for patients to present with symptoms to trigger detection and treatment, which fails over 60% of the time. At a cost of over $70,000 per revision, the annual cost of PJI to the US healthcare system is $1.2 billion.

Synotrac identifies the presence of infection in vivo, and alerts patients and physicians in real time via smartphone app to catch the infection before bacteria has formed a protective layer and the implant must be replaced. The device quickly analyzes the body’s immune response, and can be used regularly to give a dynamic picture of the joint’s healing process. Analyzing these trends enables early infection detection and personal patient care.

We have patented our proprietary detection technology and are sole owners of the IP. Synotrac is the only solution to periprosthetic joint infection that emphasizes a change in behavior: from reacting to symptoms to proactively monitoring the healing process for onset of infection. This novel process enables early detection and avoidance of revision surgery, saving money and improving patient outcomes.

Company’s Keywords:

biotechnology, medical devices, life sciences, medical, health care, periprosthetic joint infection, infection detection